Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245179 · ClinicalTrials.gov registry record · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
A Phase 1 study of Sickle Cell Disease, sponsored by Abdullah Kutlar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01245179: Recruiting Phase 1 study of Sickle Cell Disease, sponsored by Abdullah Kutlar.
NCT01245179 is a Phase 1 study of Sickle Cell Disease that is actively recruiting participants, run by Abdullah Kutlar. The registered enrollment target is 18 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01245179, a Phase 1 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Abdullah Kutlar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor. HDAC inhibitors have been shown to significantly increase hemoglobin F induction, which is well documented to improve outcomes in sickle cell disease. HDAC inhibitors are also known to potently inhibit cell-specific inflammation, which is a primary contributor to the debilitating effects of sickle cell disease. Given the relevance of these mechanisms of action in SCD, panobinostat may prove to contribute significantly to the management of SCD patients, a population in critical need of further effective treatment options.
Primary Outcome
To determine the safety and dose limiting toxicities of escalating doses of oral panobinostat in sickle cell disease
Conditions Studied
Interventions
- DRUG panobinostat
Study Locations (1)
Georgia
- Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-11 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT01245179 shows while recruiting
NCT01245179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which panobinostat is the first listed.
NCT01245179 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT01245179 about?
NCT01245179 is a clinical study titled "Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease". The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor. HDAC inhibitors have been shown to significantly increase hemoglobin F inducti...
What is the current status of trial NCT01245179?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-11. Estimated completion is 2027-01.
What conditions does trial NCT01245179 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT01245179?
The interventions under investigation include: panobinostat (DRUG).
Who is sponsoring clinical trial NCT01245179?
This trial is sponsored by Abdullah Kutlar, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01245179 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01245179's enrollment target sits among peer trials
18 182nd of 213 higher than 31 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
-
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
- NCT03326310 · 18 participants · Phase 1
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia